Table 1.
The patients’ characteristics at diagnosis according to myelofibrosis (n = 316)
| MF = 0/1 (n = 273) | MF = 2/3 (n = 43) | P | |
|---|---|---|---|
| Age (years), median, range | 52 (14–83) | 52 (21–79) | 0.705 |
| Gender, no. (%) | |||
| Male | 181 (66.3%) | 27 (62.8%) | 0.652 |
| Female | 92 (33.7%) | 16 (37.2%) | |
| Median WBC (range), × 109/L | 2.66 (0.27–13.47) | 2.73 (1.10–12.00) | 0.609 |
| Median NE (range), × 109/L | 0.99 (0.02–11.34) | 0.85 (0.04–4.92) | 0.794 |
| Median HGB (range), g/L | 69 (26–150) | 67 (30–138) | 0.291 |
| Median PLT (range), × 109/L | 53 (1–408) | 47 (3–282) | 0.911 |
| MDS subtypes (WHO, 2016), no. (%) | 0.243 | ||
| MDS-SLD | 11 (4.0%) | 2 (4.7%) | |
| MDS-MLD | 52 (19.1%) | 4 (9.3%) | |
| MDS-RS-SLD | 2 (0.7%) | 2 (4.7%) | |
| MDS-RS-MLD | 8 (2.9%) | 3 (7.0%) | |
| MDS with isolated 5q-deletion | 2 (0.7%) | 0 (0.0%) | |
| MDS-EB-1 | 70 (25.7%) | 10 (23.2%) | |
| MDS-EB-2 | 118 (43.2%) | 21 (48.8%) | |
| MDS-U | 10 (3.7%) | 1 (2.3%) | |
| Cytogenetic | 0.001 | ||
| Normal karyotype | 148 (54.2%) | 12 (27.9%) | |
| Aberrant karyotype | 125 (45.8%) | 31 (72.1%) | |
| IPSS-R risk group, no. (%) | 0.859 | ||
| Very low | 4 (1.5%) | 0 (0.0%) | |
| Low | 29 (10.6%) | 5 (11.6%) | |
| Intermediate | 65 (23.8%) | 9 (20.9%) | |
| High | 84 (30.8%) | 12 (27.9%) | |
| Very high | 91 (33.3%) | 17 (39.6%) | |
| Treatment, no. (%) | 0.170 | ||
| Allogeneic HSCT | 121 (44.3%) | 20 (46.5%) | |
| Cytoreductive treatments without HSCT | 90 (33.0%) | 12 (27.9%) | |
| HMA | 68 (25.0%) | 10 (23.2%) | |
| Chemotherapy combined with HMA | 20 (7.3%) | 2 (4.7%) | |
| AML-like chemotherapy | 2 (0.7%) | 0 (0.0%) | |
| Immunoregulatory | 11 (4.0%) | 5 (11.6%) | |
| Supportive care | 51 (18.7%) | 6 (14.0%) | |
| Leukemia transformation, no. (%) | 50 (18.3%) | 8 (18.6%) | 0.964 |
| Median time from diagnosis to leukemia transformation, months (range) | 12 (2–31) | 7 (1–20) | 0.043 |
MF myelofibrosis, WBC white blood cell count, NE neutrophils, HGB hemoglobin, PLT platelet, MDS-SLD MDS with single-lineage dysplasia, MDS-MLD MDS with ring sideroblasts with multilineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts with single-lineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts with multilineage dysplasia, MDS-EB MDS with excess of blasts, MDS-U MDS unclassifiable, HSCT hematopoietic stem cell transplantation, HMA hypomethylating agents, AML acute myeloid leukemia